Impact of COVID-19 on the market for STEM CELL MANUFACTURING globally

The newest novel coronavirus, COVID-19, is the infectious disease that it causes. A combination of well-known pharmaceutical businesses and small start-ups moved up to create cures and vaccinations after the WHO formally designated the epidemic a pandemic. In terms of operational and personnel management, the bioprocessing sector has undergone radical upheaval. Most businesses creating equipment for the production of stem cells are better able to handle staff disruptions and other problems brought on by COVID-19. Non-essential employees working from home are included in this, while onsite or essential employees work shifts with little to no movement.

Clinical trials were impacted in the case of R&D efforts because there were delays in enrolling new clinical trial participants and keeping current patients on medicines. To combat this pandemic, researchers have discovered novel cures and treatments. Stem cells have recently been shown to be a successful treatment for pulmonary illnesses, especially COVID-19. MSC-derived stem cell therapies have demonstrated promise for the treatment of the condition. As a result, there are more clinical trials being conducted with MSCs. Clinical trials for stem cell therapies to be utilised in the treatment of COVID-19 are being conducted in nations like the US, Spain, the UK, France, Belgium, and Mexico.

However, the market for stem cell therapy shrank in 2020 as a result of widespread lockdowns, refusal of wound care services, and postponed or cancelled elective surgeries & treatments. The market for stem cell production has suffered because of this downturn in the stem cell therapy sector. A number of businesses assert that a limitation in the supply of their items caused a decline in sales.

Dynamics of the stem cell manufacturing market

Growing stem cell research venture capital investments as a driver

Effective illness management and specialised research projects like personalised medicine and genetic testing both rely heavily on stem cells. Various public and private stakeholders around the world are spending more in the creation of stem cell-based technologies as a result of rising awareness of the therapeutic potential of stem cells and the scarcity of effective therapeutic treatments for rare diseases.

Request Access Full Report is Available:@

Restrictions: High operating costs related to stem cell banking and manufacturing.

Specialized methods are required for the separation, purification, and storage of stem cells (such as expansion, differentiation, cell culture media preparation, and cryopreservation). Furthermore, scaling up the production of stem cell lines and associated accessories is frequently accompanied by considerable technological challenges that impede the whole manufacturing process and add significantly to operational costs. Therefore, compared to pharmaceutical medications and biologics, stem cell products are frequently more expensively priced.

Possibility: A favourable regulatory environment for developing nations

Emerging nations (including South Korea, India, and China) are bolstering their domestic stem cell industry through a variety of regulatory measures meant to promote the development and study of stem cell therapies. In the coming ten years, favourable regulatory environments across developing nations are anticipated to offer both domestic and foreign competitors in the stem cell manufacturing market significant growth potential.

In terms of product, the consumables sector held the greatest market share for stem cell production in 2020.

Consumables, tools, and stem cell lines make up the market segments for stem cell manufacturing according to product. In 2020, consumables dominated the market. The high proportion of this market can be ascribed to the expanding need for stem cell therapies, rising stem cell research, and frequent consumable purchases.

In terms of application, the research applications sector held the greatest market share for stem cell production in 2020.

The stem cell manufacturing market is divided into three application categories based on use: research, clinical, and cell & tissue banking. Due to an increasing emphasis on stem cell cytology and pathophysiology research as well as rising public-private investment for the development and commercialization of stem cell products, the research application segment dominated the market in 2020.

The pharmaceutical & biotechnology firms segment held the greatest market share for stem cell manufacturing in 2020, according to end-user.

The pharmaceutical and biotechnology industries, academic institutions, research laboratories and contract research organisations, hospitals and surgical centres, cell banks and tissue banks, and other end users make up the end-user segments of the stem cell production market. In 2020, the pharmaceutical and biotechnology industries predominated. The significant market share of this sector can be attributable to the pharma and biotech industries’ increasing emphasis on strategic activities (such as partnerships, acquisitions, and collaborations) to increase their stem cell research capacities.

Request a Sample Copy of the Research Report:@

In 2020, North America held the greatest market share for stem cell production.

The stem cell manufacturing market was dominated by North America in 2020, followed by Europe. The vast continuing stem cell research initiatives and the accessibility of public-private financing and grants to promote the clinical evaluation of stem cells for a range of applications can be credited for the large proportion of the North American regional segment.

Important Market Players

The key players in the stem cell manufacturing market are Thermo Fisher Scientific (US), Merck Millipore (Germany), Lonza Group AG (Switzerland), Danaher Corporation (US), and Sartorius AG (Germany).

The market for manufacturing stem cells is divided into the following segments and subsegments in the study:

By Product

  • Consumables
    • Culture Media
    • Other Consumables
  • Instruments
    • Bioreactors and Incubators
    • Cell Sorters
    • Other Instruments
  • Stem Cell Lines
    • Hematopoietic stem cells (HSC)
    • Mesenchymal stem cells (MSC)
    • Induced Pluripotent Stem cells (iPSC)
    • Embryonic stem cells (ESC)
    • Neural Stem cells (NSC)
    • Multipotent adult progenitor stem cells

By Application

  • Research Applications
    • Life science research
    • Drug discovery and development
  • Clinical Application
    • Allogenic stem cell therapy
    • Autologous stem cell therapy
  • Cell & Tissue Banking Applications

By End User

  • Pharmaceutical & Biotechnology Companies
  • Academic institutes, Research laboratories & contract research organizations
  • Hospitals & surgical centres
  • Cell & tissue banks
  • Other End Users

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Rest of Asia Pacific
  • Latin America
  • Middle East and Africa


By Tanaji

Leave a Reply

Your email address will not be published. Required fields are marked *